Altocare Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 16-12-2024
- Paid Up Capital ₹ 3.00 M
as on 16-12-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -39.23%
(FY 2021)
- Profit -66.52%
(FY 2021)
- Ebitda -231.60%
(FY 2021)
- Net Worth 0.49%
(FY 2021)
- Total Assets 27.73%
(FY 2021)
About Altocare Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 3.00 M, as per Ministry of Corporate Affairs (MCA) records.
Revoori Swetha, David Bandi, and Pratima Mucharla serve as directors at the Company.
- CIN/LLPIN
U72200TG2008PTC057916
- Company No.
057916
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Feb 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Altocare Life Sciences Private Limited offer?
Altocare Life Sciences Private Limited offers a wide range of products and services, including Measuring Equipments & Instruments, Calibrating Machine, Antidepressant & Anti Anxiety Medicines, Pregabalin Capsules.
Who are the key members and board of directors at Altocare Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
David Bandi  | Managing Director | 01-Jan-2009 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Revoori Swetha | Director | 16-Jul-2021 | Current |
| Pratima Mucharla | Director | 29-Feb-2008 | Current |
Financial Performance of Altocare Life Sciences.
Altocare Life Sciences Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 39.23% decrease. The company also saw a substantial fall in profitability, with a 66.52% decrease in profit. The company's net worth moved up by a moderate rise of 0.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Altocare Life Sciences?
In 2021, Altocare Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Altocare Life Sciences?
Unlock and access historical data on people associated with Altocare Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Altocare Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Altocare Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
